Improvements in Blood Sugar and Weight Show Unclear Effects on Employment and Marriage
Contradictory Findings in Other Studies
Experts: "Adjust Expectations"

A recent study found that while medications in the glucagon-like peptide-1 (GLP-1) class, prescribed for obesity and diabetes, can improve weight and physical health, it is difficult to conclude that these drugs automatically lead to improvements in other aspects of life, such as mental health, employment, or marriage.


Image extracted by AI showing weight loss transformation

Image extracted by AI showing weight loss transformation

View original image

According to the American health media outlet Prevention, a research team led by Professor Robert Kaestner and Quiping Xi Man at the University of Chicago announced in a preprint paper released via the National Bureau of Economic Research (NBER) that the use of GLP-1 class drugs by diabetes patients was not associated with clear changes in mental health, employment, or marital status.


The researchers analyzed adults with diabetes using data from the U.S. Medical Expenditure Panel Survey from 2012 to 2023. They followed the same individuals over time, examining depressive symptoms, psychological distress, self-evaluated health status, as well as employment and marital status before and after medication use.


The team analyzed outcomes at approximately one year and again at about two years after starting the medication, but found no significant changes in employment, job loss, marriage, divorce, or mental health measures. The researchers explained that use of GLP-1 class medications did not show a meaningful association with these indicators. However, they pointed out that this analysis alone cannot be used to fully judge factors such as personal confidence or the quality of relationships.

Other Studies Find "Positive Effects on Mental Health"

There are, however, previous studies reporting that GLP-1 class drugs may have a positive impact on mental health. A Swedish study published in The Lancet Psychiatry in April analyzed about 95,000 diabetes patients diagnosed with depression or anxiety disorders. This research found that use of semaglutide, the active ingredient in Wegovy and Ozempic, was associated with a 44% reduction in risk of worsening depression and a 38% reduction in risk of worsening anxiety disorders.


In another preliminary study released in June, the marriage or cohabitation rate of single women who had been using GLP-1 class medication for over one year and six months was found to be 29 percentage points higher, while the employment rate increased by 27 percentage points among women who were initially unemployed. However, these changes were not observed in women who were already married or employed. Because the study subjects and outcome measures differed, the results are not directly comparable.

Experts Say "Lifestyle Changes Needed for Mental Health Improvement"

Mir Ali, a weight loss specialist at Orange Coast Medical Center in California, commented that patients often feel better overall after improvements in weight and health induced by medication. However, he pointed out that such drugs cannot resolve relationship or health problems that arise from causes other than weight.


Thea Gallagher, a psychologist at NYU Langone Health, similarly explained that while medication may influence appetite, weight, physical condition or confidence, it does not automatically restore troubled relationships or provide job satisfaction and successful social life. She remarked, "People may expect that losing weight will naturally bring happiness, success, and love, but in reality, there are many other factors involved." To achieve better relationships or improved mental health, she noted, counseling, communication, and changes in lifestyle may also be necessary.



Experts emphasized that this research does not mean there were no psychological or social changes for all individuals. They explained that, even if there is no significant overall change in the group average, individual experiences may differ.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing